TY - JOUR
T1 - Association between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis
AU - Joshi, Aditya A.
AU - Lerman, Joseph B.
AU - Dey, Amit K.
AU - Sajja, Aparna P.
AU - Belur, Agastya D.
AU - Elnabawi, Youssef A.
AU - Rodante, Justin A.
AU - Aberra, Tsion M.
AU - Chung, Jonathan
AU - Salahuddin, Taufiq
AU - Natarajan, Balaji
AU - Dave, Jenny
AU - Goyal, Aditya
AU - Groenendyk, Jacob W.
AU - Rivers, Joshua P.
AU - Baumer, Yvonne
AU - Teague, Heather L.
AU - Playford, Martin P.
AU - Bluemke, David A.
AU - Ahlman, Mark A.
AU - Chen, Marcus Y.
AU - Gelfand, Joel M.
AU - Mehta, Nehal N.
N1 - Publisher Copyright:
© 2018 American Medical Association. All rights reserved.
PY - 2018/10
Y1 - 2018/10
N2 - Importance: Inflammation is critical to atherosclerosis. Psoriasis, a chronic inflammatory disease associated with early cardiovascular events and increased aortic vascular inflammation (VI), provides a model to study the process of early atherogenesis. Fludeoxyglucose F 18 positron emission tomography/computed tomography (18F-FDG PET/CT) helps quantify aortic VI, and coronary computed tomography angiography provides coronary artery disease (CAD) assessment through evaluation of total plaque burden (TB) and noncalcified coronary plaque burden (NCB), luminal stenosis, and high-risk plaques (HRP). To our knowledge, association between aortic VI and broad CAD indices has not yet been assessed in a chronic inflammatory disease state. Such a study may provide information regarding the utility of aortic VI in capturing early CAD. Objective: To assess the association between aortic VI and CAD indices, including TB, NCB, luminal stenosis, and HRP prevalence, in psoriasis. Design, Setting, and Participants: In a cross-sectional cohort study at the National Institutes of Health, 215 consecutive patients with psoriasis were recruited from surrounding outpatient dermatology practices. All patients underwent 18F-FDG PET/CT for aortic VI assessment, and 190 of 215 patients underwent coronary computed tomography angiography to characterize CAD. The study was conducted between January 1, 2013, and May 31, 2017. Data were analyzed in March 2018. Exposures: Aortic VI assessed by 18F-FDG PET/CT. Main Outcomes and Measures: Primary outcome: TB and NCB. Secondary outcomes: luminal stenosis and HRP. Results: Among 215 patients with psoriasis (mean [SD] age, 50.4 [12.6] years; 126 men [59%]), patients with increased aortic VI had increased TB (standardized β = 0.48; P <.001), and higher prevalence of luminal stenosis (OR, 3.63; 95% CI, 1.71-7.70; P =.001) and HRP (OR, 3.05; 95% CI, 1.42-6.47; P =.004). The aortic VI and TB association was primarily driven by NCB (β = 0.49; P <.001), whereas the aortic VI and HRP association was driven by low-attenuation plaque (OR, 5.63; 95% CI, 1.96-16.19; P =.001). All associations of aortic VI remained significant after adjustment for cardiovascular risk factors: aortic VI and TB (β = 0.23; P <.001), NCB (β = 0.24; P <.001), luminal stenosis (OR, 3.40; 95% CI, 1.40-8.24; P =.007), and HRP (OR, 2.72; 95% CI, 1.08-6.83; P =.03). No association was found between aortic VI and dense-calcified coronary plaque burden. Conclusions and Relevance: Aortic VI is associated with broad CAD indices, suggesting that aortic VI may be a surrogate for early CAD. Larger prospective studies need to assess these associations longitudinally and examine treatment effects on these outcomes.
AB - Importance: Inflammation is critical to atherosclerosis. Psoriasis, a chronic inflammatory disease associated with early cardiovascular events and increased aortic vascular inflammation (VI), provides a model to study the process of early atherogenesis. Fludeoxyglucose F 18 positron emission tomography/computed tomography (18F-FDG PET/CT) helps quantify aortic VI, and coronary computed tomography angiography provides coronary artery disease (CAD) assessment through evaluation of total plaque burden (TB) and noncalcified coronary plaque burden (NCB), luminal stenosis, and high-risk plaques (HRP). To our knowledge, association between aortic VI and broad CAD indices has not yet been assessed in a chronic inflammatory disease state. Such a study may provide information regarding the utility of aortic VI in capturing early CAD. Objective: To assess the association between aortic VI and CAD indices, including TB, NCB, luminal stenosis, and HRP prevalence, in psoriasis. Design, Setting, and Participants: In a cross-sectional cohort study at the National Institutes of Health, 215 consecutive patients with psoriasis were recruited from surrounding outpatient dermatology practices. All patients underwent 18F-FDG PET/CT for aortic VI assessment, and 190 of 215 patients underwent coronary computed tomography angiography to characterize CAD. The study was conducted between January 1, 2013, and May 31, 2017. Data were analyzed in March 2018. Exposures: Aortic VI assessed by 18F-FDG PET/CT. Main Outcomes and Measures: Primary outcome: TB and NCB. Secondary outcomes: luminal stenosis and HRP. Results: Among 215 patients with psoriasis (mean [SD] age, 50.4 [12.6] years; 126 men [59%]), patients with increased aortic VI had increased TB (standardized β = 0.48; P <.001), and higher prevalence of luminal stenosis (OR, 3.63; 95% CI, 1.71-7.70; P =.001) and HRP (OR, 3.05; 95% CI, 1.42-6.47; P =.004). The aortic VI and TB association was primarily driven by NCB (β = 0.49; P <.001), whereas the aortic VI and HRP association was driven by low-attenuation plaque (OR, 5.63; 95% CI, 1.96-16.19; P =.001). All associations of aortic VI remained significant after adjustment for cardiovascular risk factors: aortic VI and TB (β = 0.23; P <.001), NCB (β = 0.24; P <.001), luminal stenosis (OR, 3.40; 95% CI, 1.40-8.24; P =.007), and HRP (OR, 2.72; 95% CI, 1.08-6.83; P =.03). No association was found between aortic VI and dense-calcified coronary plaque burden. Conclusions and Relevance: Aortic VI is associated with broad CAD indices, suggesting that aortic VI may be a surrogate for early CAD. Larger prospective studies need to assess these associations longitudinally and examine treatment effects on these outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85053657298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053657298&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2018.2769
DO - 10.1001/jamacardio.2018.2769
M3 - Article
C2 - 30208407
AN - SCOPUS:85053657298
SN - 2380-6583
VL - 3
SP - 949
EP - 956
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 10
ER -